O2CC6H4NO2-m(1-) | 16885-78-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O2CC6H4NO2-m(1-)
• 英文别名: 3-nitrobenzoate；3-nitro-benzoic acid; deprotonated form；3-nitro-benzoate anion
• CAS: 16885-78-2
• 化学式: C₇H₄NO₄
• 分子量: 166.113
• InChiKey: AFPHTEQTJZKQAQ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O2CC6H4NO2-m(1-) 以 甲醇 为溶剂， 生成 间硝基苯甲酸
  参考文献：
  名称：

  Ka Values of Weak Organic Acids in Protic Solvents Obtained from Their First Hyperpolarizabilities in Solution

  摘要：

  The first hyperpolarizabilities (beta) of some weak aromatic organic acids have been measured in protic solvents by the hyper-Rayleigh scattering (HRS) technique at low concentrations. The measured hyperpolarizability (beta(m)) varies between the two extreme limits: the hyperpolarizability of the acid form (beta(HA)) at the lower side and that of the basic form (beta(A-)) at the higher side. The degree of dissociation (alpha) of the acid in a solvent is related to the measured hyperpolarizability, beta(m), by the following relationship: beta(m)(2)=(1-alpha)beta(HA)(2)+alpha beta(A-)(2). The calculated beta's including solvent effects in terms of an Onsager field do not reproduce the experimentally measured hyperpolarizabilities. Other solvent-induced effects like hydrogen bonding and van der Waals interactions seem to influence the first hyperpolarizability and, thus, indirectly the extent of dissociation of these weak acids in these protic solvents.

  DOI：

  10.1021/j100051a014
• 作为产物：
  描述：

  间硝基苯甲酸 在 溴棕三甲铵 作用下， 以 水 为溶剂， 生成 O2CC6H4NO2-m(1-)
  参考文献：
  名称：

  超声吸收法研究阳离子胶束对芳族羧酸水解反应动力学的影响

  摘要：

  在水溶液中存在十四烷基三甲基溴化铵（TTAB）胶束的情况下，通过超声吸收法对羧酸的原位动力学进行了动力学研究。研究的羧酸分为两类，一类能够形成分子内氢键，即水杨酸衍生物（SAD），另一类不能形成该键，即苯甲酸衍生物（BAD）。所述速率常数（γ 2 ķ ˚F，ķ b），表观解离常数（ķ一个），并且将反应（Δ的体积变化V获得）。不同的K a关于分子内氢键的影响讨论了SAD和BAD观察到的速率常数的依赖性。还观察到SAD和BAD的ΔV的p K a依赖性。这些依赖性大于水溶液中的依赖性。该结果归因于胶束溶液和水溶液中水分子在溶质周围的排列方式的变化。

  DOI：

  10.1039/ft9949000869

文献信息

• [EN] PROCESS FOR THE CATALYTIC DIRECTED CLEAVAGE OF AMIDE-CONTAINING COMPOUNDS<br/>[FR] PROCÉDÉ POUR LE CLIVAGE CATALYTIQUE DIRIGÉ DE COMPOSÉS CONTENANT UN AMIDE
  申请人：UNIV ANTWERPEN

  公开号：WO2017046133A1

  公开（公告）日：2017-03-23

  The present invention relates to a catalytic method for the conversion of amide-containing compouds by means of a build-in directing group and upon the action of a heteronucleophilic compound (in se an amine (RNH2 or RNHR') or an alcohol (ROH) or a thiol (RSH)) in the presence of a metal catalyst to respectively esters, thioesters, carbonates, thiocarbonates and to what is defined as amide-containing compounds (such as carboxamides, urea, carbamates, thiocarbamates). The present invention also relates to these amide-containing compounds having a build-in directing group (DG), as well as the use of such directing groups in the catalytic directed cleavage of N-DG amides with the use of heteronucleophiles (in se an amine (RNH2 or RNHR') or an alcohol (ROH) or thiol (RSH)).

  本发明涉及一种催化方法，通过内置导向基团和在异核亲核化合物的作用下（例如胺（RNH2或RNHR'）或醇（ROH）或硫醇（RSH））在金属催化剂存在下将酰胺含有化合物分别转化为酯、硫酯、碳酸酯、硫代碳酸酯以及所定义的酰胺含有化合物（如羧酰胺、脲、氨基甲酸酯、硫代氨基甲酸酯）。本发明还涉及具有内置导向基团（DG）的这些酰胺含有化合物，以及在催化定向裂解N-DG酰胺时使用此类导向基团与异核亲核化合物（例如胺（RNH2或RNHR'）或醇（ROH）或硫醇（RSH））的用途。
• [EN] PYRROLOPYRIDINE-2-CARBOXYLIC ACID HYDRAZIDES<br/>[FR] HYDRAZIDES D'ACIDE PYRROLOPYRIDINE-2-CARBOXYLIQUE UTILISES COMME INHIBITEURS DE LA GLYCOGENE PHOSPHORYLASE
  申请人：PROSIDION LTD

  公开号：WO2005085245A1

  公开（公告）日：2005-09-15

  Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth.

  化合物式(I)或其药用可接受的盐是糖原磷酸化酶的抑制剂，可用于预防或治疗糖尿病、高血糖、高胆固醇血症、高胰岛素血症、高脂血症、高血压、动脉粥样硬化或组织缺血，例如心肌缺血，或作为心脏保护剂或异常细胞生长的抑制剂。
• [EN] 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES DE PHENYLE 1,3,5-SUBSTITUES UTILES COMME INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2005103020A1

  公开（公告）日：2005-11-03

  The present invention is directed to 1,3,5-phenyl substituted derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及1,3,5-苯基取代衍生物化合物，这些化合物是β-分泌酶的抑制剂，可用于治疗β-分泌酶参与的疾病，例如阿尔茨海默病。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在治疗β-分泌酶参与疾病中的用途。
• [EN] PYRROLIDIN-3-YL COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] COMPOSES PYRROLIDIN-3-YLE UTILES EN TANT QU'INHIBITEURS DE LA BETA-SECRETASE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK & CO INC

  公开号：WO2006002004A1

  公开（公告）日：2006-01-05

  The present invention is directed to pyrrolidin-3-yl derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及吡咯烷-3-基衍生物化合物，这些化合物是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• [EN] HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] DERIVES D'HYDROXYETHYLAMINE UTILISES POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：GLAXO GROUP LTD

  公开号：WO2004050619A1

  公开（公告）日：2004-06-17

  The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated - amyloid levels or -amyloid deposits, particularly Alzheimer's disease.

  本发明涉及具有Asp2（-分泌酶，BACE1或Memapsin）抑制活性的新型羟乙基胺化合物的化学式（I）：（I），其制备方法，含有它们的组合物以及它们在治疗由高β-淀粉样蛋白水平或β-淀粉样蛋白沉积所特征的疾病中的应用，特别是阿尔茨海默病。